Treatment of Pituitary Gigantism in X-linked Acrogigantism When Prior Surgery or Somatostatin Analog Has Not Controlled GH and IGF-1

Clinical Scenario

X-linked acrogigantism (X-LAG) is caused by duplications on chromosome Xq26.3 involving the gene GPR101, making it the earliest-onset form of pituitary gigantism described. Affected patients typically present with markedly increased height and weight beginning in the first 12 to 36 months of life, with these features becoming increasingly prominent over time.

Prior Treatment — Why Escalation Is Needed

This protocol addresses the situation where the first-line approach has not achieved adequate control of excess GH and IGF-1 secretion. First-line options include surgical complete resection of the tumor and/or hyperplasia, or a first-generation somatostatin analog (octreotide or lanreotide). When those measures fail to reach hormonal control targets, a next-line strategy is required.

Next-Line Approach (Partial Overview)

Following extensive surgical resection (debulking), a specific somatostatin analog strategy can be employed as second-line therapy. The complete agent selection, sequencing, and management algorithm are detailed in the full protocol.

Treatment Goals

Reduction or sustained control of GH and IGF-1 levels.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/B978-0-12-814537-1.00002-6

Duplications on chromosome Xq26.3 involving the gene GPR101 are responsible for X-LAG, the earliest onset form of pituitary gigantism described.

Patients with X-LAG typically develop signs of overgrowth in the first 12–36 months of life, with increased height and weight becoming increasingly prominent over time.

In cases where extensive surgical resection (debulking) has taken place, second line therapy with somatostatin analogs can reduce or control GH and IGF-1 in some cases.

View source ↗